Tuesday, November 6, 2007

October 2007

In September, the US Food and Drug Direction (FDA) approved the gear functionary in a new taxon of antibiotics called cyclic lipopeptide antibacterial agents. Cubicin (daptomycin) is indicated for the handling of complicated skin and skin social organization infections caused by gram-positive microorganisms.
Daptomycin binds to bacterial membranes and causes a rapid depolarization of tissue layer potency.
The loss of sheet potency leads to action of protein, DNA, and RNA abstract thought, which results in bacterial cell state.
This month’s newspaper column reviews FDA new creation approvals and labeling changes for:
Antidiabetic Agents Prandin (repaglinide) Tablets
Antidepressant Agents Paxil CR (paroxetine HCl) Tablets
Anti-infective Agents Cipro XR (ciprofloxacin) Extended-Release Tablets Cleocin (clindamycin phosphate) Toilet articles Cubicin (daptomycin) for Medical aid
Antipsychotic Agents Abilify (aripiprazole) Tablets
Antiviral Agents Valcyte (valganciclovir HCI) Tablets
Cardiovascular Agents Lopressor (metoprolol tartrate) Medical aid & Tablets Lotrel (amlodipine and benazepril HCl) Capsules
Immune Globulin Gamunex (Immune Globulin Intravenous [Human], 10% by Chromatography Process)
Oral Contraceptives Seasonale (levonorgestrel/ethinyl estradiol) Tablets
This is a part of article October 2007 Taken from "Cipro (Ciprofloxacin) Common & Detailed Reviews" Information Blog

No comments: